baldness, male patternTrials & approvals
Veradermics reports positive data for its oral treatment targeting male pattern baldness, potentially paving the way for the first new approval in decades. The therapy may face competition from existing generics and over-the-counter options.
The results could support the first approval in decades for an oral medicine that can treat male pattern baldness, though the therapy will face competition from generics and over-the-counter medications.
Original title: “Veradermics soars on positive data for baldness treatment”